Retrospective Study on Implantation of Autologous-Cultured Osteoblasts for the Treatment of Patients with Avascular Necrosis of the Femoral Head
Authors Palekar G, Bhalodiya HP, Archik S, Trivedi K
Received 10 September 2020
Accepted for publication 11 December 2020
Published 3 February 2021 Volume 2021:13 Pages 15—23
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Clark Hung
Gauresh Palekar,1 HP Bhalodiya,2 Shreedhar Archik,3 Kalpesh Trivedi4
1Orthopedic Surgeon, Surya Orthopedic Clinic, Mumbai, Maharashtra, India; 2Orthopedic Surgeon, Walk-Fit Saviour Hospital, Ahmedabad, Gujarat, India; 3Orthopedic Surgeon, Dr. Sreedhar Aarchik Orthopedic Care Clinic, Dadar West, Mumbai, Maharashtra, India; 4Arthroscopy Surgeon, Aastha Arthroscopy and Joint Surgery Clinic, Ahmedabad, Gujarat, India
Correspondence: Gauresh Palekar
Surya Orthopedic Clinic, 173/D, Sanzgiri Sadan, J S S Road, Mumbai, Maharashtra, 400004, India
Purpose: Osteonecrosis of the femoral head is a progressive and debilitating disease that causes pain, osteoarthritis and hip joint collapse, eventually necessitating hip replacement. This study evaluated the long-term outcomes of autologous adult live-cultured osteoblasts (AALCO) implantation in patients with osteonecrosis of femoral head.
Patients and Methods: In this retrospective multicenter study, we collated and analyzed data of patients ≥ 12 years of age who underwent AALCO (OSSGROW®) between 2010 and 2015 for the treatment of osteonecrosis of the femoral head.
Results: Data from 64 patients (101 hip joints) were assessed in this study. The mean ±SD duration of disease since diagnosis of osteonecrosis was 7.4± 1.6 years. The mean follow-up duration was 6.3± 1.4 years. The mean VAS score (n=98 hips) reduced significantly from 58.8 ± 13.8 to 32.2 ± 32.1 post-operatively (mean difference: − 26.5± 35.2, p=0.001) and Harris hip score (n=97 hips) also significantly improved from 47.1± 12.3 to 63.7± 27.7 post-operatively (mean difference:16.7± 28.7, p=0.0001). Following the AALCO treatment, 29 hips in 13 patients (28.7%) underwent total hip replacement (THA), indicating that AALCO treatment could delay THA for 71.3% of hips. A total of 39.1% of hips diagnosed in early stage versus 60.8% in the late stage of osteonecrosis required THA. Overall, 60.4% of hips improved, 2% remained stable, and 37.6% progressed following the AALCO implantation. The condition of disease was found to have improved in 71.1% of patients in early stage (Grades I and II) versus 58% in the late stage (Grades III and IV) of osteonecrosis.
Conclusion: Patients with osteonecrosis who received implantation of autologous-cultured osteoblasts using AALCO showed improvement in joint function and decrease in pain. Treatment with AALCO halted progression of osteonecrosis, preserved the natural hip, and eliminated the need for hip replacement surgeries in 7 out of 10 patients.
Keywords: autologous adult live-cultured osteoblasts, osteonecrosis, total hip replacement, femoral head
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]